These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30390804)

  • 1. Knowledge-Based Approaches to Off-Target Screening.
    McMasters DR
    Methods Enzymol; 2018; 610():311-323. PubMed ID: 30390804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on ion channel transporters as a target for the drug discovery].
    Imaizumi Y; Kaneko S
    Nihon Yakurigaku Zasshi; 2011 Dec; 138(6):227. PubMed ID: 22303567
    [No Abstract]   [Full Text] [Related]  

  • 3. [Screening methods for ion-channels drug discovery and new ideas].
    Fujii M; Ohya S; Yamamura H; Imaizumi Y
    Nihon Yakurigaku Zasshi; 2011 Dec; 138(6):229-33. PubMed ID: 22156258
    [No Abstract]   [Full Text] [Related]  

  • 4. The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs.
    Fan F; Toledo Warshaviak D; Hamadeh HK; Dunn RT
    PLoS One; 2019; 14(1):e0204378. PubMed ID: 30605479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High-throughput Screening Technology for Selective Inhibitors of Transporters and Its Application in Drug Discovery].
    Motoyaji T
    Yakugaku Zasshi; 2021; 141(4):511-515. PubMed ID: 33790118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class Collaborative Filtering and Its Application to Drug Repurposing.
    Lim H; Poleksic A; Yao Y; Tong H; He D; Zhuang L; Meng P; Xie L
    PLoS Comput Biol; 2016 Oct; 12(10):e1005135. PubMed ID: 27716836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hit-to-Lead: Hit Validation and Assessment.
    Hevener KE; Pesavento R; Ren J; Lee H; Ratia K; Johnson ME
    Methods Enzymol; 2018; 610():265-309. PubMed ID: 30390802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. eCounterscreening: using QSAR predictions to prioritize testing for off-target activities and setting the balance between benefit and risk.
    Sheridan RP; McMasters DR; Voigt JH; Wildey MJ
    J Chem Inf Model; 2015 Feb; 55(2):231-8. PubMed ID: 25551659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of small molecule inhibitors for the C. elegans caspase CED-3 by high-throughput screening.
    Brantley SJ; Cotten SW; Lamson DR; Smith GR; Liu R; Williams KP
    Biochem Biophys Res Commun; 2017 Sep; 491(3):773-779. PubMed ID: 28733033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic interventions in mammalian cells; applications and uses in high-throughput screening and drug discovery.
    Hampton SL; Kinnaird AI
    Cell Biol Toxicol; 2010 Feb; 26(1):43-55. PubMed ID: 19904619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solubility and permeability measurement and applications in drug discovery.
    Burton PS; Goodwin JT
    Comb Chem High Throughput Screen; 2010 Feb; 13(2):101-11. PubMed ID: 20053165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Array-Based Ligand Discovery Platform for Proteins With Short Half-Lives.
    Leifer BS; Doyle SK; Richters A; Evans HL; Koehler AN
    Methods Enzymol; 2018; 610():191-218. PubMed ID: 30390799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modern drug discovery technologies: opportunities and challenges in lead discovery.
    Guido RV; Oliva G; Andricopulo AD
    Comb Chem High Throughput Screen; 2011 Dec; 14(10):830-9. PubMed ID: 21843147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.
    Donato MT; Gómez-Lechón MJ; Tolosa L
    Expert Opin Drug Discov; 2017 Feb; 12(2):201-211. PubMed ID: 27936962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.
    Sanders JM; Beshore DC; Culberson JC; Fells JI; Imbriglio JE; Gunaydin H; Haidle AM; Labroli M; Mattioni BE; Sciammetta N; Shipe WD; Sheridan RP; Suen LM; Verras A; Walji A; Joshi EM; Bueters T
    J Med Chem; 2017 Aug; 60(16):6771-6780. PubMed ID: 28418656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting RNA structures in diseases with small molecules.
    Shao Y; Zhang QC
    Essays Biochem; 2020 Dec; 64(6):955-966. PubMed ID: 33078198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of new technologies for cellular screening along the drug value chain.
    Möller C; Slack M
    Drug Discov Today; 2010 May; 15(9-10):384-90. PubMed ID: 20206290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of chemistry-based functional proteomics to screening for novel drug targets.
    Yuan K; Lei Y; Huang C
    Comb Chem High Throughput Screen; 2010 Jun; 13(5):414-21. PubMed ID: 20156143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).
    Callis R; Rabow A; Tonge M; Bradbury R; Challinor M; Roberts K; Jones K; Walker G
    J Biomol Screen; 2015 Jul; 20(6):748-59. PubMed ID: 25851036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.